Microsoft shares jump after fourth-quarter earnings beat on AI-fueled cloud growth
EMERYVILLE, Calif. – Amyris, Inc., a leader in synthetic biology, has taken full ownership of a precision fermentation plant in Brazil following the dissolution of its RealSweet joint venture with Ingredion Incorporated (NYSE: INGR), a global ingredient solutions provider with a market capitalization of $8.9 billion. The announcement was made today, marking a significant shift in the partnership between the two companies.
Under the terms of the agreement, Amyris will have complete control over the Barra Bonita plant, which is expected to bolster its production capabilities in the region. In exchange, Ingredion will have exclusive rights to use Amyris’ technology for the production and commercialization of fermented Reb M, a high-intensity sweetener. According to InvestingPro data, Ingredion maintains a strong financial position with a "GREAT" overall health score and operates with a moderate level of debt.
The collaboration between Amyris and Ingredion began with the aim to leverage Amyris’ advanced precision fermentation technology to produce sustainable ingredients for the food industry. With this new arrangement, both companies anticipate continued commercial success and potential future partnerships.
Amyris is recognized for its two decades of experience in the field of industrial biotechnology, creating sustainable ingredients for a wide range of consumer products. Its technology allows for the rapid and scalable co-creation of innovative ingredients, catering to the increasing demand for sustainable and economically viable alternatives.
Ingredion, with its global presence and extensive portfolio, serves a diverse set of markets, including food, beverage, animal nutrition, and industrial sectors. The company’s annual net sales in 2024 were reported to be around $7.4 billion, with a healthy gross profit margin of 25% and strong cash flows that adequately cover interest payments. InvestingPro analysis reveals 8 additional key insights about Ingredion’s financial performance and market position.
This strategic move is poised to enhance Amyris’ operational efficiency and expand its product offerings, while Ingredion will benefit from a unique technology to strengthen its position in the sweetener market. With a remarkable 28-year track record of consistent dividend payments and trading at an attractive valuation according to InvestingPro’s Fair Value analysis, Ingredion appears well-positioned for this new phase of growth as both companies continue to navigate the dynamic landscape of ingredient manufacturing.
The information in this article is based on a press release statement.
In other recent news, Ingredion Incorporated reported a notable earnings beat for the first quarter of 2025. The company’s earnings per share (EPS) reached $2.97, significantly exceeding analysts’ projections of $2.41, marking a 23.2% surprise. However, the revenue for the quarter was $1.81 billion, which fell short of expectations by 2.2%. Despite this revenue miss, Ingredion provided a positive outlook by raising its EPS guidance for 2025 to a range of $10.90 to $11.60, with expectations for cash from operations between $825 million and $950 million for the year. Additionally, the company held its annual stockholders’ meeting, where all 11 nominees for the Board of Directors were re-elected. Stockholders also approved the compensation of the company’s named executive officers and ratified KPMG LLP as the independent registered public accounting firm. These developments reflect ongoing investor confidence in Ingredion’s governance and executive leadership.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.